{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:48:31Z","timestamp":1791478111669,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972869"],"award-info":[{"award-number":["81972869"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      As an important N6-methyladenosine (m\n                      <jats:sup>6<\/jats:sup>\n                      A) regulator, abnormal expression of methyltransferase-like protein 3 (METTL3) has been reported in certain human cancers. Although some data have shown that METTL3 plays an essential role in the progression of clear-cell renal cell carcinoma RCC (ccRCC), the detailed mechanism still remains largely undetermined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Immunohistochemistry (IHC) assay was used to examine the expression of METTL3 and its clinical implications in human ccRCC by using tissue-microarray (TMA). The cellular models based on ccRCC cell lines such as 786-O and ACHN, were established by operating METTL3 and HHLA2 via knockdown or overexpression, followed by in vitro cellular function studies and in vivo subcutaneous transplantation tumor model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We found that METTL3 expression in ccRCC tissues was significantly higher compared with adjacent normal tissues. We also found the overall survival (OS) of the patients with low METTL3 expression was significantly better compared with the patients with high METTL3 expression. Furthermore, HHLA2\n                      <jats:sup>high<\/jats:sup>\n                      METTL3\n                      <jats:sup>high<\/jats:sup>\n                      could serve as a better prognostic predictor for ccRCC patients. Depletion of METTL3 could significantly inhibit the cell viability, migration, and invasion abilities in ccRCC cell lines. Cellular studies further revealed that METTL3 could regulate HHLA2 expression via m\n                      <jats:sup>6<\/jats:sup>\n                      A modification of HHLA2 mRNA. In vitro studies revealed that HHLA2 overexpression could reverse the inhibition of cellular functions mediated by METTL3 depletion. The subcutaneous transplantation tumor model confirmed that HHLA2 overexpression could reverse the inhibition of tumor growth mediated by METTL3 depletion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study indicated that METTL3 served as an important prognostic predictor for ccRCC patients, and we demonstrated a novel regulatory mechanism of HHLA2 by mRNA epigenetic modification via METTL3. Moreover, we found that the METTL3\/HHLA2 axis could promote tumorigenesis of ccRCC. Collectively, our current findings provided new insights into the therapeutic strategy against this malignancy targeting METTL3.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-022-03496-3","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T04:04:05Z","timestamp":1657080245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Dawei","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3128-9762","authenticated-orcid":false,"given":"Jingting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"issue":"12","key":"3496_CR1","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/s41581-020-0316-3","volume":"16","author":"CM Diaz-Montero","year":"2020","unstructured":"Diaz-Montero CM, Rini BI, Finke JH. The immunology of renal cell carcinoma. Nat Rev Nephrol. 2020;16(12):721\u201335.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"3496_CR2","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/CCO.0b013e3282f9782b","volume":"20","author":"BI Rini","year":"2008","unstructured":"Rini BI, Rathmell WK, Godley P. Renal cell carcinoma. Curr Opin Oncol. 2008;20(3):300\u20136.","journal-title":"Curr Opin Oncol"},{"issue":"13","key":"3496_CR3","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.3390\/ijms21134691","volume":"21","author":"D Lavacchi","year":"2020","unstructured":"Lavacchi D, Pellegrini E, Palmieri VE, Doni L, Mela MM, Di Maida F, Amedei A, Pillozzi S, Carini M, Antonuzzo L. Immune checkpoint inhibitors in the treatment of renal cancer: current state and future perspective. Int J Mol Sci. 2020;21(13):4691.","journal-title":"Int J Mol Sci"},{"issue":"7627","key":"3496_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature19796","volume":"539","author":"WF Chen","year":"2016","unstructured":"Chen WF, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma YQ, Patel N, Yell P, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016;539(7627):112.","journal-title":"Nature"},{"issue":"3","key":"3496_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/SPC.0000000000000363","volume":"12","author":"S Nazzani","year":"2018","unstructured":"Nazzani S, Bazinet A, Karakiewicz PI. Role of immunotherapy in kidney cancer. Curr Opin Support Palliat Care. 2018;12(3):325\u201333.","journal-title":"Curr Opin Support Palliat Care"},{"key":"3496_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12935-019-0813-2","volume":"19","author":"LJ Chen","year":"2019","unstructured":"Chen LJ, Zhu DW, Feng J, Zhou Y, Wang Q, Feng HJ, Zhang JP, Jiang JT. Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients. Cancer Cell Int. 2019;19:101.","journal-title":"Cancer Cell Int"},{"issue":"16","key":"3496_CR7","doi-asserted-by":"publisher","first-page":"5150","DOI":"10.1158\/1078-0432.CCR-08-0536","volume":"14","author":"PL Crispen","year":"2008","unstructured":"Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, et al. Tumor cell and tumor vasculature expression of B7\u2013H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008;14(16):5150\u20137.","journal-title":"Clin Cancer Res"},{"issue":"27","key":"3496_CR8","doi-asserted-by":"publisher","first-page":"10391","DOI":"10.1073\/pnas.0600937103","volume":"103","author":"AE Krambeck","year":"2006","unstructured":"Krambeck AE, Thompson RH, Dong HD, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. B7\u2013H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA. 2006;103(27):10391\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"3496_CR9","doi-asserted-by":"publisher","first-page":"e000157","DOI":"10.1136\/jitc-2019-000157","volume":"8","author":"QH Zhou","year":"2020","unstructured":"Zhou QH, Li KW, Chen X, He HX, Peng SM, Peng SR, Wang Q, Li ZA, Tao YR, Cai WL, et al. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. J Immunother Cancer. 2020;8(1):e000157.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3496_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/imr.12521","volume":"276","author":"M Janakiram","year":"2017","unstructured":"Janakiram M, Shah UA, Liu WF, Zhao AM, Schoenberg MP, Zang XX. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7\u2013H3. Immunol Rev. 2017;276(1):26\u201339.","journal-title":"Immunol Rev"},{"issue":"18","key":"3496_CR11","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1158\/0008-5472.CAN-21-0468","volume":"81","author":"X Qiu","year":"2021","unstructured":"Qiu X, Yang S, Wang S, Wu J, Zheng B, Wang K, Shen S, Jeong S, Li Z, Zhu Y, et al. M6A demethylase ALKBH5 regulates PD-L1 expression and tumor immunoenvironment in intrahepatic cholangiocarcinoma. Cancer Res. 2021;81(18):4778\u201393.","journal-title":"Cancer Res"},{"key":"3496_CR12","doi-asserted-by":"publisher","first-page":"715674","DOI":"10.3389\/fcell.2021.715674","volume":"9","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Zhou H, Shi J, Guan A, Zhu Y, Hou Z, Li R. Decreased m6A modification of CD34\/CD276(B7\u2013H3) leads to immune escape in colon cancer. Front Cell Dev Biol. 2021;9:715674.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"3496_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bbrc.2020.06.153","volume":"530","author":"N Tsuruta","year":"2020","unstructured":"Tsuruta N, Tsuchihashi K, Ohmura H, Yamaguchi K, Ito M, Ariyama H, Kusaba H, Akashi K, Baba E. RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells. Biochem Biophys Res Commun. 2020;530(1):235\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"3496_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fonc.2020.00003","volume":"10","author":"J Wang","year":"2020","unstructured":"Wang J, Zhang C, He W, Gou X. Effect of m(6)A RNA methylation regulators on malignant progression and prognosis in renal clear cell carcinoma. Front Oncol. 2020;10:3.","journal-title":"Front Oncol"},{"issue":"1","key":"3496_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13045-020-00951-w","volume":"13","author":"C Zeng","year":"2020","unstructured":"Zeng C, Huang W. Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020;13(1):117.","journal-title":"J Hematol Oncol"},{"issue":"7608","key":"3496_CR16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nature18298","volume":"534","author":"X Wang","year":"2016","unstructured":"Wang X, Feng J, Xue Y, Guan Z, Zhang D, Liu Z, Gong Z, Wang Q, Huang J, Tang C, et al. Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex. Nature. 2016;534(7608):575\u20138.","journal-title":"Nature"},{"issue":"2","key":"3496_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nchembio.1432","volume":"10","author":"J Liu","year":"2014","unstructured":"Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, Jia G, Yu M, Lu Z, Deng X, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10(2):93\u20135.","journal-title":"Nat Chem Biol"},{"issue":"4","key":"3496_CR18","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s13238-018-0518-7","volume":"10","author":"J Huang","year":"2019","unstructured":"Huang J, Dong X, Gong Z, Qin LY, Yang S, Zhu YL, Wang X, Zhang D, Zou T, Yin P, et al. Solution structure of the RNA recognition domain of METTL3-METTL14 N(6)-methyladenosine methyltransferase. Protein Cell. 2019;10(4):272\u201384.","journal-title":"Protein Cell"},{"issue":"2","key":"3496_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.molcel.2016.05.041","volume":"63","author":"P Wang","year":"2016","unstructured":"Wang P, Doxtader KA, Nam Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol Cell. 2016;63(2):306\u201317.","journal-title":"Mol Cell"},{"key":"3496_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.omtn.2019.11.022","volume":"19","author":"W Zhao","year":"2020","unstructured":"Zhao W, Qi X, Liu L, Ma S, Liu J, Wu J. Epigenetic regulation of m(6)A modifications in human cancer. Mol Ther Nucleic Acids. 2020;19:405\u201312.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"3496_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1101\/gr.212563.116","volume":"27","author":"L Ma","year":"2017","unstructured":"Ma L, Zhao B, Chen K, Thomas A, Tuteja JH, He X, He C, White KP. Evolution of transcript modification by N(6)-methyladenosine in primates. Genome Res. 2017;27(3):385\u201392.","journal-title":"Genome Res"},{"issue":"7","key":"3496_CR22","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1136\/gutjnl-2019-319639","volume":"69","author":"Q Wang","year":"2020","unstructured":"Wang Q, Chen C, Ding Q, Zhao Y, Wang Z, Chen J, Jiang Z, Zhang Y, Xu G, Zhang J, et al. METTL3-mediated m(6)A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut. 2020;69(7):1193\u2013205.","journal-title":"Gut"},{"issue":"4","key":"3496_CR23","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1053\/j.gastro.2020.11.013","volume":"160","author":"H Chen","year":"2021","unstructured":"Chen H, Gao S, Liu W, Wong CC, Wu J, Wu J, Liu D, Gou H, Kang W, Zhai J, et al. RNA N(6)-methyladenosine methyltransferase METTL3 facilitates colorectal cancer by activating the m(6)A-GLUT1-mTORC1 axis and is a therapeutic target. Gastroenterology. 2021;160(4):1284-1300.e1216.","journal-title":"Gastroenterology"},{"issue":"1","key":"3496_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12943-019-1036-9","volume":"18","author":"J Han","year":"2019","unstructured":"Han J, Wang JZ, Yang X, Yu H, Zhou R, Lu HC, Yuan WB, Lu JC, Zhou ZJ, Lu Q, et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221\/222 maturation in m6A-dependent manner. Mol Cancer. 2019;18(1):110.","journal-title":"Mol Cancer"},{"issue":"7","key":"3496_CR25","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00262-011-1017-3","volume":"60","author":"LJ Chen","year":"2011","unstructured":"Chen LJ, Sun J, Wu HY, Zhou SM, Tan Y, Tan M, Shan BE, Lu BF, Zhang XG. B7\u2013H4 expression associates with cancer progression and predicts patient\u2019s survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother. 2011;60(7):1047\u201355.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3496_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000486219","volume":"45","author":"L Chen","year":"2018","unstructured":"Chen L, Zhai W, Zheng X, Xie Q, Zhou Q, Tao M, Zhu Y, Wu C, Jiang J. Decreased IFIT2 expression promotes gastric cancer progression and predicts poor prognosis of the patients. Cell Physiol Biochem. 2018;45(1):15\u201325.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"3496_CR27","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1038\/s41467-019-09903-6","volume":"10","author":"H Wang","year":"2019","unstructured":"Wang H, Hu X, Huang M. Mettl3-mediated mRNA m(6)A methylation promotes dendritic cell activation. Nature Commun. 2019;10(1):1898.","journal-title":"Nature Commun"},{"issue":"1","key":"3496_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-019-1109-9","volume":"18","author":"L He","year":"2019","unstructured":"He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176.","journal-title":"Mol Cancer"},{"key":"3496_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.canlet.2017.11.018","volume":"415","author":"X Cai","year":"2018","unstructured":"Cai X, Wang X, Cao C, Gao Y, Zhang S, Yang Z, Liu Y, Zhang X, Zhang W, Ye L. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g. Cancer Lett. 2018;415:11\u20139.","journal-title":"Cancer Lett"},{"issue":"6","key":"3496_CR30","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.18632\/aging.101856","volume":"11","author":"J Zhou","year":"2019","unstructured":"Zhou J, Wang J, Hong B, Ma K, Xie H, Li L, Zhang K, Zhou B, Cai L, Gong K. Gene signatures and prognostic values of m6A regulators in clear cell renal cell carcinoma\u2014a retrospective study using TCGA database. Aging. 2019;11(6):1633\u201347.","journal-title":"Aging"},{"key":"3496_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12935-020-01238-3","volume":"20","author":"J Chen","year":"2020","unstructured":"Chen J, Yu K, Zhong G, Shen W. Identification of a m(6)A RNA methylation regulators-based signature for predicting the prognosis of clear cell renal carcinoma. Cancer Cell Int. 2020;20:157.","journal-title":"Cancer Cell Int"},{"key":"3496_CR32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12935-020-01238-3","volume":"20","author":"J Chen","year":"2020","unstructured":"Chen J, Yu K, Zhong G, Shen W. Identification of a m(6)A RNA methylation regulators-based signature for predicting the prognosis of clear cell renal carcinoma. Cancer Cell Int. 2020;20:157.","journal-title":"Cancer Cell Int"},{"issue":"11","key":"3496_CR33","first-page":"1233","volume":"3","author":"JA Bokar","year":"1997","unstructured":"Bokar JA, Shambaugh ME, Polayes D, Matera AG, Rottman FM. Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase. RNA. 1997;3(11):1233\u201347.","journal-title":"RNA"},{"issue":"10","key":"3496_CR34","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1357-2725(01)00071-1","volume":"33","author":"RA Leach","year":"2001","unstructured":"Leach RA, Tuck MT. Expression of the mRNA (N6-adenosine)-methyltransferase S-adenosyl-L-methionine binding subunit mRNA in cultured cells. Int J Biochem Cell Biol. 2001;33(10):984\u201399.","journal-title":"Int J Biochem Cell Biol"},{"issue":"6","key":"3496_CR35","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1002\/hep.29683","volume":"67","author":"M Chen","year":"2018","unstructured":"Chen M, Wei L, Law CT, Tsang FH, Shen J, Cheng CL, Tsang LH, Ho DW, Chiu DK, Lee JM, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2018;67(6):2254\u201370.","journal-title":"Hepatology"},{"issue":"1","key":"3496_CR36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s13046-019-1408-4","volume":"38","author":"W Peng","year":"2019","unstructured":"Peng W, Li J, Chen R, Gu Q, Yang P, Qian W, Ji D, Wang Q, Zhang Z, Tang J, et al. Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246\/SPRED2\/MAPK signaling pathway. J Exp Clin Cancer Res. 2019;38(1):393.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7724","key":"3496_CR37","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-018-0538-8","volume":"561","author":"J Choe","year":"2018","unstructured":"Choe J, Lin S, Zhang W, Liu Q, Wang L, Ramirez-Moya J, Du P, Kim W, Tang S, Sliz P, et al. mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature. 2018;561(7724):556\u201360.","journal-title":"Nature"},{"key":"3496_CR38","doi-asserted-by":"publisher","first-page":"669750","DOI":"10.3389\/fimmu.2021.669750","volume":"12","author":"W Guo","year":"2021","unstructured":"Guo W, Tan F, Huai Q, Wang Z, Shao F, Zhang G, Yang Z, Li R, Xue Q, Gao S, et al. Comprehensive analysis of PD-L1 expression, immune infiltrates, and m6A RNA methylation regulators in esophageal squamous cell carcinoma. Front Immunol. 2021;12:669750.","journal-title":"Front Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03496-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03496-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03496-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T04:07:09Z","timestamp":1657080429000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03496-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3496"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03496-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]},"assertion":[{"value":"9 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human subjects: all patients gave informed consent for participation, and the protocol for the present study was approved by the ethics committee of the Third Affiliated Hospital of Soochow University. Animals: animal handling and all experimental procedures were performed in accordance with applicable regulations and guidelines and approved by Soochow University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"298"}}